Sio Capital Management 13F annual report
Sio Capital Management is an investment fund managing more than $265 billion ran by Jin Lee. There are currently 43 companies in Mrs. Lee’s portfolio. The largest investments include Labcorp and Teleflex, together worth $73.4 billion.
$265 billion Assets Under Management (AUM)
As of 7th August 2024, Sio Capital Management’s top holding is 245,902 shares of Labcorp currently worth over $50 billion and making up 18.9% of the portfolio value.
Relative to the number of outstanding shares of Labcorp, Sio Capital Management owns more than approximately 0.1% of the company.
In addition, the fund holds 111,078 shares of Teleflex worth $23.4 billion, whose value fell 6.8% in the past six months.
The third-largest holding is Zimmer Biomet Inc worth $16.9 billion and the next is Smith & Nephew plc worth $14.4 billion, with 579,619 shares owned.
Currently, Sio Capital Management's portfolio is worth at least $265 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Sio Capital Management
The Sio Capital Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Jin Lee serves as the Chief Compliance Officer at Sio Capital Management.
Recent trades
In the most recent 13F filing, Sio Capital Management revealed that it had opened a new position in
Labcorp and bought 245,902 shares worth $50 billion.
This means they effectively own approximately 0.1% of the company.
Labcorp makes up
27.5%
of the fund's Health Care sector allocation and has grown its share price by 3.0% in the past year.
The investment fund also strengthened its position in Teleflex by buying
77,200 additional shares.
This makes their stake in Teleflex total 111,078 shares worth $23.4 billion.
Teleflex soared 1.9% in the past year.
On the other hand, there are companies that Sio Capital Management is getting rid of from its portfolio.
Sio Capital Management closed its position in Laboratory Corporation Of America Holdings on 14th August 2024.
It sold the previously owned 225,902 shares for $49.4 billion.
Jin Lee also disclosed a decreased stake in Cigna by 0.6%.
This leaves the value of the investment at $8.85 billion and 26,786 shares.
One of the smaller hedge funds
The two most similar investment funds to Sio Capital Management are Missouri Trust & Investment Co and Phraction Management. They manage $265 billion and $265 billion respectively.
Jin Lee investment strategy
Sio Capital Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 68.7% of
the total portfolio value.
The fund focuses on investments in the United States as
48.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
16% of the total holdings value.
On the other hand, small-cap stocks make up 11.6% of the portfolio.
The average market cap of the portfolio companies is close to $18 billion.
The complete list of Sio Capital Management trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Labcorp Holdings Inc. |
Opened
245,902
|
$50,043,516,000 | 18.88% |
| Laboratory Corporation Of America Holdings |
Closed
225,902
|
$49,350,551,000 | |
| Teleflex Incorporated |
227.88%
111,078
|
$23,363,036,000 | 8.81% |
| Globus Medical Inc |
Closed
393,420
|
$21,103,049,000 | |
| Zimmer Biomet Holdings Inc |
109.36%
155,304
|
$16,855,143,000 | 6.36% |
| Smith & Nephew plc |
Opened
579,619
|
$14,362,959,000 | 5.42% |
| Madrigal Pharmaceuticals Inc |
Closed
51,000
|
$13,619,040,000 | |
| Organon & Co |
26.95%
608,096
|
$12,587,587,000 | 4.75% |
| GSK Plc |
18.43%
312,000
|
$12,012,000,000 | 4.53% |
| Corbus Pharmaceuticals Hldgs |
Opened
225,165
|
$10,188,716,000 | 3.84% |
| Vaxart Inc |
Opened
14,764,991
|
$9,852,678,000 | 3.72% |
| Tyra Biosciences Inc |
12.05%
600,294
|
$9,598,701,000 | 3.62% |
| Abbott Laboratories |
Opened
89,500
|
$9,299,945,000 | 3.51% |
| Medtronic Plc |
Closed
105,000
|
$9,150,750,000 | |
| Cigna Group (The) |
64.80%
26,786
|
$8,854,648,000 | 3.34% |
| Kenvue Inc |
Opened
485,000
|
$8,817,300,000 | 3.33% |
| Disc Medicine Inc |
Opened
192,000
|
$8,653,440,000 | 3.26% |
| Embecta Corp |
Closed
585,418
|
$7,768,497,000 | |
| Erasca Inc |
18.43%
2,874,536
|
$6,783,905,000 | 2.56% |
| Biodesix Inc |
Opened
4,347,855
|
$6,652,218,000 | 2.51% |
| Humacyte Inc |
Closed
2,000,000
|
$6,220,000,000 | |
| Healthcare Services Group, Inc. |
Closed
421,317
|
$5,258,036,000 | |
| Fusion Pharmaceuticals Inc. |
Closed
243,035
|
$5,181,506,000 | |
| Scholar Rock Holding Corp |
Closed
273,720
|
$4,861,267,000 | |
| Integra Lifesciences Holdings Corp |
Closed
137,000
|
$4,856,650,000 | |
| Astria Therapeutics Inc |
24.37%
510,267
|
$4,643,430,000 | 1.75% |
| ANI Pharmaceuticals Inc |
17.87%
71,740
|
$4,568,403,000 | 1.72% |
| Bausch Plus Lomb Corp |
Opened
302,710
|
$4,395,349,000 | 1.66% |
| Pmv Pharmaceuticals Inc |
Opened
2,708,408
|
$4,387,621,000 | 1.66% |
| Zymeworks Inc |
Opened
491,128
|
$4,179,499,000 | 1.58% |
| Ocular Therapeutix Inc |
Closed
383,026
|
$3,485,537,000 | |
| CytomX Therapeutics Inc |
Closed
1,598,590
|
$3,484,926,000 | |
| BridgeBio Pharma Inc |
38.39%
125,174
|
$3,170,657,000 | 1.20% |
| Apogee Therapeutics Inc |
No change
78,000
|
$3,069,300,000 | 1.16% |
| Context Therapeutics Inc |
Opened
1,328,352
|
$2,663,346,000 | 1.00% |
| Modular Med Inc |
No change
1,539,352
|
$2,432,176,000 | 0.92% |
| Stoke Therapeutics, Inc. |
22.26%
175,301
|
$2,368,317,000 | 0.89% |
| Revance Therapeutics Inc |
Closed
468,871
|
$2,306,845,000 | |
| Enanta Pharmaceuticals Inc |
No change
177,004
|
$2,295,742,000 | 0.87% |
| Third Harmonic Bio Inc |
No change
163,363
|
$2,123,719,000 | 0.80% |
| Nuvation Bio Inc |
50.00%
668,115
|
$1,950,896,000 | 0.74% |
| Ars Pharmaceuticals Inc |
59.37%
217,864
|
$1,854,023,000 | 0.70% |
| Ventyx Biosciences Inc |
106.06%
778,924
|
$1,799,314,000 | 0.68% |
| COMPASS Pathways plc |
Opened
293,417
|
$1,772,239,000 | 0.67% |
| Arcutis Biotherapeutics Inc |
74.90%
159,626
|
$1,484,522,000 | 0.56% |
| X4 Pharmaceuticals, Inc. |
30.34%
2,499,800
|
$1,449,884,000 | 0.55% |
| IDEAYA Biosciences, Inc. |
Closed
33,007
|
$1,448,347,000 | |
| Ironwood Pharmaceuticals Inc |
Closed
149,400
|
$1,301,274,000 | |
| Prelude Therapeutics Inc |
No change
320,394
|
$1,220,701,000 | 0.46% |
| Aprea Therapeutics, Inc. |
No change
276,603
|
$1,125,774,000 | 0.42% |
| RAPT Therapeutics, Inc. |
No change
315,000
|
$960,750,000 | 0.36% |
| Avalo Therapeutics Inc |
603.95%
71,458
|
$891,081,000 | 0.34% |
| Foghorn Therapeutics Inc. |
No change
121,672
|
$699,614,000 | 0.26% |
| Boundless Bio Inc |
13.33%
162,058
|
$627,164,000 | 0.24% |
| Vincerx Pharma Inc |
Closed
102,049
|
$516,368,000 | |
| Verastem Inc |
Opened
133,412
|
$397,568,000 | 0.15% |
| Nyxoah S A |
No change
50,839
|
$354,348,000 | 0.13% |
| Nextcure Inc |
No change
130,000
|
$206,700,000 | 0.08% |
| ASLAN Pharmaceuticals Ltd |
No change
254,150
|
$76,245,000 | 0.03% |
| No transactions found | |||
| Showing first 500 out of 59 holdings | |||
Hedge funds similar to Sio Capital Management
- Permit Capital
- Coyle Counsel
- Great Oak Capital Partners
- One Fin Capital Management L.P.
- Linden Advisors L.P.
- Phraction Management
- Missouri Trust & Investment Co
- Brown University
- Mccarthy & Cox
- Saturn V Capital Management L.P.
- Ribbit Capital Gp Ii
- Fiduciary Planning
- Prospect Capital Advisors
- Promethos Capital